<DOC>
	<DOCNO>NCT02431988</DOCNO>
	<brief_summary>The purpose study administer novel cluster differentiation antigen 19 ( CD19 ) specific Chimeric Antigen Receptor T-cells ( CAR19 T-cells ) patient relapse resistant Diffuse Large B Cell Lymphoma ( DLBCL ) ass safety efficacy strategy bridge allogeneic transplantation .</brief_summary>
	<brief_title>Evaluation CAR19 T-cells Optimal Bridge Allogeneic Transplantation</brief_title>
	<detailed_description>Patients Diffuse Large B Cell Lymphoma ( DLBCL ) resistant relapse follow rituximab-containing chemotherapy regimens poor prognosis . Patients may receive salvage chemotherapy possibly autologous stem cell transplant ( auto-SCT ) . A proportion patient , however , respond chemotherapy may relapse auto-SCT therefore require novel treatment option . Such patient may benefit allogeneic stem cell transplantation ( allo-STC ) . In study investigator aim administer CAR19 T-cells act bridge transplant strategy . Specifically , ( 1 ) feasibility generate CD19 specific Chimeric Antigen Receptor T-cells call CAR19 T-cells , ( 2 ) safety administer CD19 CAR T-cells setting , ( 3 ) well CAR19 T-cells engraft ( 4 ) evaluate effective cell bridge allogeneic transplantation . Following informed consent registration trial , patient undergo unstimulated leucapheresis generation CAR19 T cell . Whilst cell generate , patient proceed cycle standard salvage ( recommended ifosfamide , epirubicin etoposide ( i.e . IVE regime ) , receive rituximab . Patients receive pre-conditioning intravenous fludarabine cyclophosphamide prior infusion single dose CAR-modified T-cells . An escalate dose protocol employ identify minimum effective dose CAR19 T-cells .</detailed_description>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Age 1665 year 2 . Confirmed diagnosis CD19+ DLBCL 3 . Primary resistant relapse disease fail achieve metabolic Complete Response ( CR ) 1st line salvage , relapse post autograft fail achieve metabolic CR follow single cycle salvage 4 . Potential allogeneic transplant candidate 5 . Agreement pregnancy test , use adequate contraception 12 month postCAR19 Tcell infusion 6 . Karnofsky performance status &gt; 60 7 . Written inform consent 1 . Women pregnant lactate 2 . Prior allogeneic transplantation 3 . Progressive disease follow recent salvage prior plan leucapheresis 4 . Prior history ischaemic heart disease , dysrhythmias , abnormal electrocardiogram ( ECG ) ( Left Bundle Branch Block ( LBBB ) ) , Multiple Gated Acquisition ( MUGA ) leave ventricular ejection fraction ( LVEF ) &lt; 40 % 5 . Exclusions proceed allogeneic transplantation ( active hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) ; liver function test ( LFT ) &gt; 3 x upper limit normal ( ULN ) ; Creatinine Clearance ( CrCl ) &lt; 40 ml/min ; comorbidity precludes transplantation ) 6 . Known central nervous system ( CNS ) involvement cerebral vascular accident ( CVA ) within prior 3 month 7 . Patients receive corticosteroid dose &gt; 10mg prednisolone per day ( equivalent ) 8 . Use rituximab within last 2 month prior CAR19 Tcell infusion 9 . Active autoimmune disease require immunosuppression 10 . Life expectancy &lt; 3 month 11 . Known allergy albumin dimethylsulfoxide ( DMSO ) 12 . Any contraindication administration use ifosfamide , epirubicin , etoposide , fludarabine cyclophosphamide .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>refractory</keyword>
	<keyword>DLBCL</keyword>
</DOC>